StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

BioCryst Pharmaceuticals's price to book ratio was 44.7× on Jan 29, 2021, against 15.5× a year earlier. Over the last 5 years it ranged from 3.1× to 392.8×, with a median of 13.1×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2021Jan 29, 202144.7×+5.6
2020Dec 31, 202039.1×+23.6
2019Jul 31, 201915.5×+3.4
2018Dec 31, 201812.1×+7.3
2017Dec 29, 20174.8×−112.1
2016Dec 30, 2016116.9×+105.1
2015Dec 31, 201511.8×+1.3
2014Dec 31, 201410.5×−121.2
2013Dec 31, 2013131.7×+124.3
2012Dec 31, 20127.4×+7.4
2011Dec 30, 20110.0×–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?